Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial

著者: Fred Saad, Antoine Thiery-Vuillemin, Paweł Wiechno, B. Yа. Alekseev, Núria Sala, Robert H. Jones, Ivo Kocák, Vincenzo Emanuele Chiurì, Jacek Jassem, Aude Fléchon, Charles H. Redfern, Jinyu Kang, Joseph E. Burgents, Christopher Gresty, Arnold Degboe, Noel W. Clarke - The Lancet 2022 被引用: 30